Answers are grounded in this paper and cite their sources.
Most of our PWS patients had improvement after short-term GH treatment, but 32% had worsening of sleep disturbance. A subset of PWS patients are at risk during this window of vulnerability shortly after initiation of GH. Because it is difficult to predict who will worsen with GH, patients with PWS should have PSA before and after starting GH and should be monitored for sleep apnea with upper respiratory tract infections. Otorhinolaryngological evaluation is warranted if sleep apnea worsens on GH. IGF-I levels should be monitored, with the goal being physiological levels.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2006) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: